Navigation Links
MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients
Date:4/1/2008

Study Continues to Show Lasting Reductions in Mitral Regurgitation Across a

Spectrum of Patients

CHICAGO, April 1, 2008 /PRNewswire/ -- Percutaneous mitral repair using the MitraClip(R) device may successfully reduce mitral regurgitation (MR) in patients suffering from functional MR (FMR) over a two-year period, according to preliminary data from the ongoing Endovascular Valve Edge-to-Edge REpair STudy (EVEREST) presented today at the SCAI Annual Scientific Sessions in Partnership with the ACC i2 Summit (SCAI-ACCi2). The EVEREST trial is evaluating the safety and efficacy of the MitraClip device for the treatment of MR, a condition in which blood leaks backward through the mitral valve, requiring the heart to work harder and ultimately leading to heart failure.

The data analysis was based on 23 patients with moderate-to-severe or severe FMR (grade 3+ to 4+). James Hermiller, M.D., director of the interventional fellowship program at St. Vincent Heart Center of Indiana in Indianapolis, presented the findings. Dr. Hermiller reported that 83 percent of the 23 FMR patients had successful MR reduction after the MitraClip procedure. Additionally, the majority (74 percent) of successfully treated FMR patients showed MR reduction to less than or equal to 2+ MR. Importantly, the MR reduction was maintained, with a Kaplan-Meier durability of MR reduction in 89 percent of patients at one and two years.

"The results have surpassed our initial expectations," said Dr. Hermiller. "This compelling preliminary data suggests that the treatment of functional MR with the MitraClip may be an effective option for patients."

Other results, showed that at one year, clinical symptoms improved or stabilized compared to baseline in 92 percent of successfully treated FMR patients (matched data, n=12). Symptomatic relief was seen in 70 percent of FMR patients who had a history of heart failure.

In addition to the reduction in M
'/>"/>

SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation
2. U. of Md. Researchers to Develop Devices to Revolutionize Drug Research
3. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
4. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
7. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
8. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
(Date:1/14/2014)... NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service the ... NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, options ...
(Date:1/14/2014)... , January 14, 2014 Equashield ... for hazardous drugs, today announced that it has ... straight year.   Equashield,s closed systems ... pharmacists, nurses and other medical professionals who prepare ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Equashield's Sales Grow by 60% in 2013 2
... ORANGE COUNTY, Calif., May 23, 2011 Applied Medical ... Healthcare (doing business as Covidien) on May 17, 2011 ... of California for infringing a recently issued Applied Medical ... Plus trocar products, Civil Action No. CV 11-4203 VBF ...
... 23, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has informed the company that it has ... be held on June 17, 2011 to discuss the Company,s ... of the neovascular form of age-related macular degeneration (wet AMD). ...
Cached Medicine Technology:Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 4
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... same odds for condition, regardless of screening , , SUNDAY, June 8 ... less risk than previously believed of having silent myocardial ischemia, a ... study. , In fact, all adults aged 55 to ... a cardiac condition whether they are screened for the problem or ...
... 7, 2008 The International Diabetes Federation (IDF) Task ... research demonstrates that type 2 diabetes and obstructive sleep ... have significant implications on public health and on individuals. ... and sleep experts who examined the impacts of untreated ...
... Organization, Carolyn,s Compassionate Children gives cancer, ... of attending college, BOSTON, June 7 ... and cancer survivor Leanna,Elizalde with a $2,500 Survivorship ... School,s graduation ceremony Saturday. Alex Oden, 20, a,two-time ...
... Distributed, Flexible, Redundant, Patient-Specific Intra-Venous, (IV) Automation Robot for Non-Hazardous ... Satellite Pharmacies, and Even ... Patient Care Workplaces, ... leader in the robotic automation of patient-specific IV,Admixtures today announced ...
... 2 diabetes risk but could suggest its causes ... identified a gene that regulates glucose levels but does ... their finding may help improve understanding of the underlying ... diagnostic of diabetes. This finding demonstrates there are gene ...
... Becomes "Susan G. Komen GLOBAL Race for the ... Mall was,passionately pink this morning, as nearly 50,000 ... the 19th annual Susan,G. Komen National Race for ... fund breast cancer research and community health programs ...
Cached Medicine News:Health News:Older Diabetics' Risk of Cardiac Ischemia Lower Than Thought 2Health News:IDF urges health care providers to address the relationship between type 2 diabetes and sleep apnea 2Health News:Nonprofit Organization Dedicated to Helping Young Adult Cancer Survivors Raises $4500 for Leanna Elizalde 2Health News:Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled, 2Health News:Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled, 3Health News:Scientists ID Gene Regulating Blood Glucose Levels 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 2Health News:19th Annual Susan G. Komen National Race for the Cure(R) Draws Nearly 50,000 Participants, Celebrities; Brings Record Funds to National Capital Area 3
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
... The Fossil Eyewear collection offers updated ... solutions and unique product features.The casual collection ... fashionable, statement-making product. , The Eyewear ... Titanium has earned it the title of ...
Inquire...
Inquire...
Medicine Products: